Sign in
Taking people in United StatesPhase 1/2

Testing GDC-1261 in people with advanced or metastatic prostate cancer

Tests GDC-1261 for safety and early effects in advanced prostate cancer.

Key facts

Who runs it
Genentech, Inc.
Where
Nashville, New Haven, and Scottsdale, United StatesSee the 3 sitesAlso in 2 other countries, 3 sites
Trial code
Registry title
A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Activity of GDC-1261 in Participants With Advanced or Metastatic Prostate Cancer
Status
Recruiting
Phase
Phase 1/2
People taking part
260 people, planned
Started
29 Apr 2026
Expected to end
30 Dec 2027
Type of study
Interventional
Treatments tested
  • GDC-1261
Record updated
5 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for men with prostate cancer that has spread and has worsened after earlier treatment. It tests the safety and activity of a drug called GDC-1261.

Age
18 years or older
Sex
Men only
Disease stage
Prostate adenocarcinoma confirmed by tissue or cell tests, with metastatic disease. The cancer has progressed during or after the last treatment.
Earlier treatment
Must still be on androgen deprivation therapy (ADT) with a GnRH agonist or antagonist, or have had both testicles removed. No approved cancer drug treatment in the last 14 days or 5 drug half-lives.

Main reasons for not taking part

  • Untreated brain or spinal fluid (CNS) metastases or leptomeningeal disease
  • Weak bone spots that may soon fracture
  • Pain that is not controlled
  • Another cancer within the last 5 years
  • Current infection, or antibiotics through a vein within 14 days or by mouth within 7 days before screening

The registry criteria, word for word

Show all 14 criteriaShow less

Who can take part

  • Eastern Cooperative Oncology Group (ECOG) Performance Status of <=1
  • Life expectancy is >= 3 months
  • Histologically or cytologically confirmed prostate adenocarcinoma
  • Disease progression during or following the direct prior line of therapy
  • Ongoing androgen deprivation therapy (ADT) with gonadotropin-releasing hormone (GnRH) agonist or antagonist, or have had bilateral orchiectomy
  • Metastatic disease
  • Adequate end organ function

Who cannot take part

  • Treatment with any approved systemic anti-cancer therapy within 14 days or 5 drug elimination half-lives
  • Infection requiring systemic IV antibiotics within 14 days or oral antibiotics within 7 days prior to screening, or any evidence of current infection
  • Untreated central nervous system (CNS) metastases or leptomeningeal disease
  • History of malignancy within 5 years
  • Any medical condition or abnormal clinical laboratory finding that, in the investigator's judgment, would preclude the individual's safe participation in and completion of the study or could affect the interpretation of the results
  • Structurally unstable bone lesions suggest an impending fracture
  • Uncontrolled pain

Where in United States

Also in 2 other countries, 3 sites

  • Sarah Cannon Research InstituteNashville, United StatesTaking people
  • Yale Cancer CenterNew Haven, United StatesTaking people
  • Honor Health Research InstituteScottsdale, United StatesTaking people

About the trial

What the trial wants to find out

The purpose of this study is to evaluate the safety, pharmacokinetics (PK), and preliminary activity of GDC-1261 in participants with advanced or metastatic prostate cancer. It's also to identify a recommended dose(s) and regimen for GDC-1261 for subsequent studies.

The group in the trial

  • Dose Escalation + ExpansionTreatment being tested

    Participants will receive GDC-1261 as per the schedule described in the protocol.

    Treatment: GDC-1261

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
A Phase I/II Dose-escalation and Expansion Study Evaluating the Safety, Pharmacokinetics, and Preliminary Activity of GDC-1261 in Patients With Advanced or Metastatic Prostate Cancer
Plain-language title
Testing GDC-1261 in people with advanced or metastatic prostate cancerGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
5 November 2026